Please login to the form below
Puma
This page shows the latest Puma news and features for those working in and with pharma, biotech and healthcare.
bluebird bio splits to create new oncology firm 2seventy bio
Following the split, bluebird bio has moved its headquarters three miles north to Assembly Row, where it said it would establish a 'biotech hub' beside another new resident, sportswear giant, Puma.
Latest news
-
Alnylam’s amyloidosis drug heads latest crop of CHMP approvals
Paediatric use drugs. During its four-day meeting, the CHMP approved two new paediatric-use marketing authorisations (PUMAs) for off-patent drugs specifically developed for use in children. ... Kigabeq (vigabatrin), the other PUMA medicine, has been
-
Sanofi’s rare blood disorder drug Cablivi set for European approval
There was good news too for Puma Biotech after the committee backed approval for its adjuvant HER2-positive breast cancer drug Nerlynx (neratinib), having rejected it at an earlier meeting in
-
Daily Brief: Europe changes mind on Puma drug, Pfizer's Healthcare Hub, AbbVie and Calico add $1bn to anti-ageing quest
The latest from pharma, biotech and healthcare. Europe changes mind on Puma’s breast cancer drug. ... The EMA's Committee for Medicinal Products for Human Use (CHMP) is set to approve the use of Puma Biotechnology’s neratinib for the extended
-
Pfizer’s leukaemia drug Mylotarg backed for use in EU
There was worse news for Puma Biotechnology - which has its application to market Nerlyx (neratinib) for breast cancer turned down - and also Pfizer whose application to extend the indications of Sutent
-
EU’s 10-year paediatric meds report - not bad, but can do better
One early finding is that the paediatric use marketing authorisation (PUMA) process - which like the orphan drug regulations is designed to provide 10 years’ market exclusivity in return for testing ... active ingredient or substitution for cheaper
More from news
Approximately 2 fully matching, plus 12 partially matching documents found.
Latest appointments
-
New hires at Amgen, Eli Lilly and Zosano
Prior to joining Zosano, Lo served as the chief commercial officer for Puma Biotechnoly, and previously worked as senior vice president and chief commercial officer at Corcept Therapeutics.
-
Constellation Pharmaceuticals strengthens management team
Senderowicz has over 20 years’ experience in the life sciences sector, with his most recent role seeing him sit on Puma Biotechnology’s board of directors. ... Prior to his time at Puma, Senderowicz held several roles for the life sciences sector
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Roche’s Polivy backed by FDA Advisory Committee for lymphoma therapy
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- LEO Pharma enters clinical trial partnership with ICON
- Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- UCB's bimekizumab shows continued improvement in hidradenitis suppurativa patients
- The Considered appoints Bam Zahraie as chief experience officer
- The impact of pharma congresses on HCPs – virtual and in person
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Cello poaches Astellas' Taylor, Con Franklin joins Ketchum, Uptake Strategies expands
- A relentless commitment to neuroscience
- Putting the ovation into innovation: trends from ESMO
- Sanofi to acquire Provention Bio in deal worth $2.9bn
- Neurodiversity and healthcare communications – do we know enough and do we do enough?
PMHub
Onyx Health
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...
Latest intelligence
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- By offering patients knowledge, skills and confidence, they empower patients to be more actively involved in their health. Holistic support can help tackle adherence, mental health or anything else patients...
